Ramon Sun

Ramon Sun covers health for The Independent with a focus on how biochemical pathways and common supplements shape the course of serious disease, especially Alzheimer’s. He writes from the vantage point of an Associate Professor of Biochemistry and Molecular Biology at the University of Florida, bringing his own research on glucosamine, brain glycogen and protein glycosylation directly into the stories he explains for a general audience. That combination of frontline metabolic research and plain-language health writing sets him apart from a generic reporter on the health beat.

Glucosamine and Alzheimer’s progression

Sun’s flagship piece at The Independent examines new evidence that people with Alzheimer’s disease who took the common joint supplement glucosamine were 25 per cent more likely to die within five years than those who did not. He presents this as the key finding of a study he and his colleagues published in the journal Nature Metabolism, and he writes in the first person as one of the scientists behind the work rather than as an outside observer. The article links a familiar over-the-counter product to faster disease progression, and he walks readers through why a supplement marketed for joint pain can have unintended consequences in the brain. Instead of stopping at the headline risk figure, he connects the clinical outcome data to underlying biochemical mechanisms, explaining how glucosamine interfaces with glycogen stores and protein glycosylation in neural tissue. The format is an evidence-led explainer: he sets out the core statistic, situates it in the context of peer-reviewed research, and then spends most of the piece unpacking what the result means for patients already living with Alzheimer’s and for people considering glucosamine use.

Metabolism and glycosylation as a lens on health

Sun’s scientific work anchors his health coverage in metabolism rather than in surface-level lifestyle trends. His research includes studies showing that brain glycogen serves as a critical glucosamine cache required for protein glycosylation, clarifying how cellular energy stores and sugar-modification pathways intersect in the central nervous system. He also contributes to metabolomics projects that track how nutrients and metabolites move through complex biochemical networks in health and disease. Those interests shape the themes he chooses to highlight at The Independent: the message is not simply that one supplement is risky, but that altering a single node in metabolism can reverberate through brain chemistry and disease trajectories. In his glucosamine piece he uses these concepts to explain why a product long perceived as benign can, in the context of Alzheimer’s, be associated with worse outcomes. The coverage is therefore less about wellness tips and more about teaching readers how metabolism-oriented research can change clinical thinking about everyday health decisions.

Audience, tone and reporting format

Sun writes for a broad health audience, but he targets people dealing with Alzheimer’s—patients, carers and clinicians—with concrete numbers and clear explanations rather than advocacy or alarm. His tone in the glucosamine article is direct and measured: he sets out the increased risk, explains the study that produced it, and then focuses on what questions the findings raise for ongoing treatment rather than offering simple prescriptions. The piece reads as an analytical column built around a single major study, not as breaking news or a short advisory; he takes the space to describe the science, the limits of the data, and the practical implications. This reporting format makes his work useful when a story needs a detailed, mechanism-aware discussion of how specific molecules, pathways or supplements intersect with long-term disease outcomes.

Research-led perspective on the health beat

Sun’s role as an Associate Professor of Biochemistry and Molecular Biology at the University of Florida is central to how he covers health. He is actively involved in research on glucosamine, brain glycogen, protein glycosylation and metabolomics, with work featured in journals such as Nature Metabolism and in major science highlights. That experience allows him to write about study design, biochemical mechanisms and clinical relevance with the precision of someone who generates the data, not just reports on it. In practice, this means his Independent coverage starts from peer-reviewed findings and moves outward to public health implications, rather than the other way around. For communications teams, he is a writer whose health stories are rooted in primary metabolic research and who is comfortable explaining complex biochemistry in accessible prose when the subject involves supplements, nutrition and neurodegenerative disease.